Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Cidara Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names The Vanguard Group (filed 2026-01-30).
Who is behind it
Cidara Therapeutics, Inc.: incorporated in Delaware; business address in San Diego, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-02-17).
Officers and directors, each with the role and the filing that names them:
- Jeffrey Stein, Ph.D.: Executive Officer, Director (Form D, 2024-05-06)
- Daniel D. Burgess: Director (Form D, 2024-05-06)
- Theodore R. Schroeder: Director (Form D, 2024-05-06)
- Bonnie Bassler, Ph.D.: Director (Form D, 2024-05-06)
- Carin Canale-Theakston: Director (Form D, 2024-05-06)
- James Merson, Ph.D.: Director (Form D, 2024-05-06)
- Ryan Spencer: Director (Form D, 2024-05-06)
- Laura Tadvalkar, Ph.D.: Director (Form D, 2024-05-06)
- Taylor Sandison, M.D.: Executive Officer (Form D, 2024-05-06)
- Preetam Shah, Ph.D.: Executive Officer (Form D, 2024-05-06)
- Leslie Tari, Ph.D.: Executive Officer (Form D, 2024-05-06)
- Shane Ward: Executive Officer (Form D, 2024-05-06)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-02-17 | Point72 Asset Management, L.P. | 1.4% |
| Schedule 13G/A, 2026-02-17 | Bcls Fund Iii Investments, LP | 0% |
| Schedule 13G/A, 2026-02-13 | Vivo Opportunity Fund Holdings, L.P. | 0% |
| Schedule 13G, 2026-01-30 | The Vanguard Group | 6.38% |
| Schedule 13D/A, 2026-01-09 | Ra Capital Management, L.P. | 0% |
| Schedule 13D/A, 2025-11-17 | Ra Capital Management, L.P. | 10.7% |
| Schedule 13G/A, 2025-11-14 | Point72 Asset Management, L.P. | 6.2% |
| Schedule 13G/A, 2025-11-14 | Commodore Capital LP | 2% |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-05-06 | $240M | $240M |
Latest IPO step: Cidara Therapeutics, Inc. filed to go public (S-1, 2024-12-23).
IPO filings: S-1, 2024-12-23, S-1, 2024-07-19; ticker CDTX on Nasdaq Capital Market.
Acquisitions reported on Form 8-K, Item 2.01: acquired by Merck Sharp & Dohme LLC (2026-01-07).
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/cidara-therapeuticsLast updated 2026-10-18
Who owns Cidara Therapeutics, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/cidara-therapeutics